SCHEMBL21695057

SCHEMBL21695057

COCCOCCOCCOC(=O)N1CCN(C(C)C)CC1

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 10/20 0.40
ALDH1A1 P00352 3/20 0.37
KDM4E B2RXH2 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
CASP6 P55212 1/20 0.36
MGLL Q99685 1/20 0.36
POLB P06746 2/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
HTT P42858 1/20 0.36
CYP2D6 P10635 1/20 0.36
KCNH2 Q12809 1/20 0.36
LMNA P02545 1/20 0.36
MMP1 P03956 1/20 0.35
MMP2 P08253 1/20 0.35
MMP3 P08254 1/20 0.35
MMP9 P14780 1/20 0.35
MMP8 P22894 1/20 0.35
MMP13 P45452 1/20 0.35
P2RY12 Q9H244 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25588991 0.88 ALDH1A1 (0.37) HRH3ALDH1A1KDM4EL3MBTL1CASP6
SCHEMBL21695058 0.88 ALDH1A1 (0.42) HRH3ALDH1A1KDM4ECASP6MGLL
SCHEMBL20436763 0.88 ALDH1A1 (0.37) HRH3ALDH1A1KDM4EL3MBTL1CASP6
SCHEMBL19661326 0.86 CASP6 (0.36) HRH3ALDH1A1KDM4EL3MBTL1CASP6
SCHEMBL19661318 0.85 ALDH1A1 (0.34) HRH3ALDH1A1KDM4EL3MBTL1CASP6
SCHEMBL21694972 0.82 ALDH1A1 (0.34) HRH3ALDH1A1KDM4EL3MBTL1CASP6
SCHEMBL15934091 0.82 KDM4E (0.44) ALDH1A1KDM4EPOLBSMN1; SMN2HTT
SCHEMBL25589656 0.80 HRH3 (0.41) HRH3ALDH1A1KDM4EL3MBTL1CASP6
SCHEMBL15932295 0.78 ALDH1A1 (0.36) ALDH1A1KDM4EPOLBSMN1; SMN2HTT
SCHEMBL681679 0.78 ALDH1A1 (0.56) ALDH1A1KDM4ECASP6MGLLPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11384105-B2 Processes for preparing oligomers SAREPTA THERAPEUTICS, INC. (US) 2022-07-12 US disclosed
US-20210198296-A1 PROCESSES FOR PREPARING OLIGOMERS SAREPTA THERAPEUTICS, INC. (US) 2021-07-01 US disclosed
US-10875880-B2 Processes for preparing oligomers SAREPTA THERAPEUTICS, INC. (US) 2020-12-29 US disclosed
US-20200040020-A1 PROCESSES FOR PREPARING OLIGOMERS JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT 2020-02-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200040020-A1 PROCESSES FOR PREPARING OLIGOMERS NOP2, PCBP1, RNGTT HRH3 4883/4885ALDH1A1 4511/4885KDM4E 4234/4885
US-20210198296-A1 PROCESSES FOR PREPARING OLIGOMERS PCBP1, RNGTT, PHAX HRH3 4880/4885ALDH1A1 4252/4885KDM4E 3847/4885
US-10875880-B2 Processes for preparing oligomers NOP2, PCBP1, RNGTT HRH3 4883/4885ALDH1A1 4511/4885KDM4E 4234/4885
US-11384105-B2 Processes for preparing oligomers NOP2, RNGTT, PCBP1 HRH3 4883/4885ALDH1A1 4482/4885KDM4E 3881/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.